Thr101
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr101  -  ATG5 (human)

Site Information
SALPWNItVHFKSFP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23084709

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 2 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 1 ) , glioblastoma ( 1 ) , glioma ( 1 ) , esophageal cancer ( 2 ) , esophageal carcinoma ( 2 ) , liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PAK1 (human) ( 1 )
Kinases, in vitro:
PAK1 (human) ( 1 )
Treatments:
FRAX597 ( 1 ) , hypoxia ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on ATG5:
molecular association, regulation ( 1 ) , protein stabilization ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
autophagy, induced ( 1 ) , carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 )
Induce interaction with:
ATG16L1 (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
glioblastoma multiforme ( 1 )

References 

1

Feng X, et al. (2020) Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5. Autophagy, 1-20
32186433   Curated Info

2

Tucker M (2010) CST Curation Set: 9225; Year: 2010; Biosample/Treatment: cell line, Kyse140/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info